Wyeth

Zoetis Services LLC

Zoetis W LLC

Wumin Li

Hsien-Jue Chu

Zhichang Xu

Nicole Rae Gibson

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

[object Object]

Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or amelioratinginfection. Administration to an animal of one or two doses of an adjuvanted live avirulentcomposition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain ofthereby reducing the severity of and/or preventing disease caused by one or more virulent strain of. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulentand compositions, comprising Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2) in further combination with an adjuvanted live avirulent

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA. In another embodiment, the invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedbacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Mycoplasma hyopneumoniae bacterin vaccine

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedbacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedbacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Growing community of inventors

Fort Dodge, IA, United States of America

Wumin Li